"Keytruda, first approved in 2014, belongs to a class of immunotherapy drugs that enable the immune system to attack cancer cells, extending survival for millions and transforming fatal diagnoses into manageable conditions."
"The investigation revealed that while Keytruda has become one of the best-selling drugs in pharmaceutical history, generating $31.7 billion in sales in 2025, access to the drug varies dramatically across regions."
"Hospitals are forced to ration treatment, and patients often turn to courts or crowdfunding to secure access to this essential medication, highlighting the stark inequalities in healthcare systems worldwide."
Keytruda, an immunotherapy drug, has revolutionized cancer treatment but also exemplifies global health inequities. An international investigation revealed how pricing, patent protections, and regulatory frameworks affect access to this life-saving drug. The project involved 124 journalists across 37 countries, gathering insights from various stakeholders. Keytruda has generated significant revenue, with 60% of sales from the U.S., while many patients face barriers to access, leading to rationing and alternative funding methods for treatment.
Read at www.dw.com
Unable to calculate read time
Collection
[
|
...
]